Poly [ADP-ribose] polymerase-1 (PARP-1) localizes rapidly to sites of DNA damage and has been associated with various repair mechanisms including base excision repair (BER) and homologous recombination/non-homologous end joining (HRR/NHEJ). PARP-1 acts by adding
poly-ADP ribose side chains to target
proteins (PARylation) altering molecular interactions and functions. Recently small molecule inhibitors of PARP-1 have been shown to have significant clinical potential and third generation
PARP inhibitors are currently being investigated in clinical trials. These drugs alone or in combination with radio/
chemotherapy have resulted in meaningful patient responses and an increase in survival in metastatic
breast cancer cases bearing BRCA-deficient or triple negative
tumors and BRCA-deficient
ovarian cancer patients.
ABT-888, a potent PARP-1 inhibitor, sensitizes many
cancer cells in-vitro and in-vivo to
temozolomide. As such, we hypothesized that
colon cancers would be sensitized to the
DNA damaging chemotherapeutic agents,
oxaliplatin and
irinotecan, by
ABT-888. Using
colon cancer cell lines significant synergy was observed between
ABT-888 and
irinotecan at concentrations of
ABT-888 as low as 0.125 μM. The level of synergy observed correlated with the degree of PARP1 inhibition as measured biochemically in cell lysates.
ABT-888 at concentrations of 0.5-4 μM resulted in synergy with
oxaliplatin. Furthermore, 24 h post treatment combinations of
ABT-888/
irinotecan generally resulted in increased G2/M cell cycle arrest and increased levels of DNA damage, followed by increased levels of apoptosis 48 h post treatment. In conclusion this study suggests that
ABT-888 may be a clinically effective adjuvant to current
colon cancer therapies that include the use of
irinotecan and/or
oxaliplatin.